EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice

Erik Zorrilla iD, Georgii Krivoshein iD, Adisa Kuburas iD, Maarten Schenke iD, Cassandra L Piña iD, Sandra H van Heiningen iD, Jayme S Waite iD, Anisa Dehghani iD, William C Castonguay, Harold C Flinn iD, Arn M J M van den Maagdenberg iD, Andrew F Russo iD und 2 weitere

Cephalalgia · 2025-02 · 45 (2)

DOI: 10.1177/03331024251314487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, online erschienen am 23.02.2025. Verfasst von Erik Zorrilla und 13 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Graduate Program, University of Iowa, Iowa City, IA, USA. Hauptthemen laut MEDLINE: Cannabidiol, Dronabinol, Migraine Disorders. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NIDA NIH HHS, Delphian Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The therapeutic use of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to treat migraine has been understudied. Using three mouse models, we examined the impact of CBD and THC on migraine-relevant behaviors triggered by: 1) calcitonin gene-related peptide (CGRP), 2) sodium nitroprusside (SNP), and 3) cortical spreading depolarization (CSD).

Methods

Both male and female CD1 mice were treated with CBD (100 mg/kg) or THC (1 mg/kg) alone or in combinations of CBD (1, 30 or 100 mg/kg) and THC (1 mg/kg) prior to injection of CGRP or SNP. The mice were assessed for light aversion (photophobia), squint (non-evoked pain), and periorbital tactile hypersensitivity, as well as possible adverse effects. In a separate set of experiments, CSD events were optogenetically induced in familial hemiplegic migraine 1 (FHM1) mutant and wildtype littermates (WT) mice (C57BL/6 background), followed by grimace and motor assessments with and without combinations of CBD (30 or 100 mg/kg) and THC (1 mg/kg).

Results

In CD1 mice, a 100:1 CBD:THC combination mitigated light aversion induced by CGRP and SNP in males and females. Rescue of CGRP- and SNP-induced squint was observed only in male mice with 100:1 CBD:THC. None of the treatments rescued periorbital tactile hypersensitivity in either sex. In FHM1 mutant and WT mice, the 100:1 CBD:THC ratio did not affect CSD characteristics but did reduce CSD-induced grimace features (i.e., head pain mimic). No adverse effects of any of the cannabinoid treatments were observed using cognitive, emotional, or motor tests.

Conclusions

A 100:1 ratio of CBD:THC has a beneficial effect on some of the most bothersome migraine-related symptoms in three mouse models. Our findings support a potential therapeutic efficacy of combined CBD and THC treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolDronabinolMigraine DisordersAnimalsMiceMaleFemaleDrug Therapy, CombinationDisease Models, AnimalCalcitonin Gene-Related Peptide

Stichwörter der Autor:innen

CGRPCSDSNPcannabinoidsheadachephotophobia

Substanzen

CannabidiolDronabinolCalcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • Neuroscience Graduate Program, University of Iowa, Iowa City, IA, USA.
  • Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, USA.
  • Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Center for the Prevention and Treatment of Visual Loss, Department of Veterans Affairs Health Center, Iowa City, IA, USA.
  • Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Neurology, University of Iowa, Iowa City, IA, USA.

ORCID-Profile: Erik Zorrilla, Georgii Krivoshein, Adisa Kuburas, Maarten Schenke, Cassandra L Piña, Sandra H van Heiningen, Jayme S Waite, Anisa Dehghani, Harold C Flinn, Arn M J M van den Maagdenberg, Andrew F Russo, Else A Tolner, Anne-Sophie Wattiez

Förderung

  • NINDS NIH HHS
  • NIDA NIH HHS
  • Delphian Therapeutics
  • Migraine Research Foundation
  • the Medical Delta program “Medical NeuroDelta: Ambulant Neuromonitoring for Prevention and Treatment of Brain Disease”
  • National Institutes of Health
  • the Dutch National Epilepsy Foundation 22-07

Zitieren

APA

Zorrilla, E., Krivoshein, G., Kuburas, A., Schenke, M., Piña, C. L., van Heiningen, S. H., Waite, J. S., Dehghani, A., Castonguay, W. C., Flinn, H. C., van den Maagdenberg, A. M. J. M., Russo, A. F., Tolner, E. A., & Wattiez, A. S. (2025). Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice. Cephalalgia, 45(2). https://doi.org/10.1177/03331024251314487

Vancouver

Zorrilla E, Krivoshein G, Kuburas A, Schenke M, Piña CL, van Heiningen SH, et al. Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice. Cephalalgia. 2025;45(2). doi:10.1177/03331024251314487

BibTeX
@article{Zorrilla2025,
  author = {Zorrilla, Erik and Krivoshein, Georgii and Kuburas, Adisa and Schenke, Maarten and Piña, Cassandra L and van Heiningen, Sandra H and Waite, Jayme S and Dehghani, Anisa and Castonguay, William C and Flinn, Harold C and van den Maagdenberg, Arn M J M and Russo, Andrew F and Tolner, Else A and Wattiez, Anne-Sophie},
  title = {Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice},
  journal = {Cephalalgia},
  year = {2025},
  volume = {45},
  number = {2},
  doi = {10.1177/03331024251314487}
}
Kostenlos starten →